179 related articles for article (PubMed ID: 7585041)
1. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Sommer N; Löschmann PA; Northoff GH; Weller M; Steinbrecher A; Steinbach JP; Lichtenfels R; Meyermann R; Riethmüller A; Fontana A
Nat Med; 1995 Mar; 1(3):244-8. PubMed ID: 7585041
[TBL] [Abstract][Full Text] [Related]
2. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
3. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
[TBL] [Abstract][Full Text] [Related]
4. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
Semmler J; Wachtel H; Endres S
Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
6. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
[TBL] [Abstract][Full Text] [Related]
7. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Folcik VA; Smith T; O'Bryant S; Kawczak JA; Zhu B; Sakurai H; Kajiwara A; Staddon JM; Glabinski A; Chernosky AL; Tani M; Johnson JM; Tuohy VK; Rubin LL; Ransohoff RM
J Neuroimmunol; 1999 Jun; 97(1-2):119-28. PubMed ID: 10408965
[TBL] [Abstract][Full Text] [Related]
8. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase.
Martínez I; Puerta C; Redondo C; García-Merino A
J Neurol Sci; 1999 Mar; 164(1):13-23. PubMed ID: 10385042
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT.
Navarro J; Punzón C; Jiménez JL; Fernández-Cruz E; Pizarro A; Fresno M; Muñoz-Fernández MA
J Virol; 1998 Jun; 72(6):4712-20. PubMed ID: 9573235
[TBL] [Abstract][Full Text] [Related]
10. The effect of rolipram on the production of cytokines in HTLV-I infected cell lines and peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy (HAM).
Hatae T; Hara H; Kobayashi T; Watanabe T
J Neurol Sci; 1997 May; 148(1):87-94. PubMed ID: 9125394
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
Sommer N; Martin R; McFarland HF; Quigley L; Cannella B; Raine CS; Scott DE; Löschmann PA; Racke MK
J Neuroimmunol; 1997 Oct; 79(1):54-61. PubMed ID: 9357447
[TBL] [Abstract][Full Text] [Related]
13. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Fujimoto T; Sakoda S; Fujimura H; Yanagihara T
J Neuroimmunol; 1999 Mar; 95(1-2):35-42. PubMed ID: 10229113
[TBL] [Abstract][Full Text] [Related]
14. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents.
Dinter H; Tse J; Halks-Miller M; Asarnow D; Onuffer J; Faulds D; Mitrovic B; Kirsch G; Laurent H; Esperling P; Seidelmann D; Ottow E; Schneider H; Tuohy VK; Wachtel H; Perez HD
J Neuroimmunol; 2000 Aug; 108(1-2):136-46. PubMed ID: 10900347
[TBL] [Abstract][Full Text] [Related]
15. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Liang L; Beshay E; Prud'homme GJ
Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
[TBL] [Abstract][Full Text] [Related]
16. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
[TBL] [Abstract][Full Text] [Related]
17. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
18. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.
Agnello D; Carvelli L; Muzio V; Villa P; Bottazzi B; Polentarutti N; Mennini T; Mantovani A; Ghezzi P
J Neuroimmunol; 2000 Sep; 109(2):105-11. PubMed ID: 10996212
[TBL] [Abstract][Full Text] [Related]
19. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.
Paintlia AS; Paintlia MK; Singh I; Singh AK
Exp Neurol; 2008 Dec; 214(2):168-80. PubMed ID: 18775426
[TBL] [Abstract][Full Text] [Related]
20. The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Jiang H; Bielekova B; Okazaki H; Clarence-Smith K; Johnson KP; Bergey G; Martin R; Dhib-Jalbut S
J Neuroimmunol; 1999 Jun; 97(1-2):134-45. PubMed ID: 10408967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
